Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
News
FDA Expands Drug’s Approval To Include More People With AML
Blood Cancer United funding supported discovery and development of breakthrough menin inhibitors.
News
Blood Cancer United, formerly The Leukemia & Lymphoma Society, Announces New Funding for Lifesaving Cancer Breakthroughs
With the latest funding round, Blood Cancer United’s cumulative research funding tops $2 billion, continuing to help increase survival rates and impro…
News
Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
Data from Master Clinical Trials—focused on transforming care for patients with acute myeloid leukemia—will be presented at ASH.
News
FDA Approves Targeted Immunotherapy for Adults with Follicular Lymphoma
“Although we are making great progress in treating follicular lymphoma, it remains incurable, and we need new treatments like epcoritamab in this chem…
News
New Guide Pulls Back the Curtain on U.S. Hospital Financing and Operations
“What to Ask (About) a Hospital” provides policymakers, journalists, advocates and patients with an ‘all-you-need-to-know’ guide to understanding hosp…
News
FDA approves new drug to treat advanced AML in adults
Blood Cancer United® funding supported menin inhibitor drugs, including ziftomenib, at every stage of scientific development.
News
Newly Approved Treatment Slows Progression to Multiple Myeloma
Latest treatment holds off progression to multiple myeloma in people with a high-risk precursor condition
News
FDA Approves Drug for People With Advanced Disease Multiple Myeloma
Belantamab mafodotin (Blenrep) in a three-drug combination is now approved for the treatment of relapsed/refractory multiple myeloma.
News
Where Your Ancestors Came From Can Influence Blood Cancer Survival Rates
Scientists are learning more every day about how mutations in an individual's genes can affect their health. But now we’re learning that differences i…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
